ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis

Guilherme S. Mazzini; Toms Augustin; Sabrena Noria; Carlos Romero-Marrero; Na Li; Bilal Hameed; Dan Eisenberg; Dan E. Azagury; Sayeed Ikramuddin

doi:10.1016/j.soard.2021.11.015

ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis

Guilherme S. Mazzini
, Toms Augustin
, Sabrena Noria
, Carlos Romero-Marrero
, Na Li
, Bilal Hameed
, Dan Eisenberg
, Dan E. Azagury
, Sayeed Ikramuddin

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	314-325
Number of pages	12
Journal	Surgery for Obesity and Related Diseases
Volume	18
Issue number	3
DOIs	https://doi.org/10.1016/j.soard.2021.11.015
State	Published - Mar 2022

Access to Document

10.1016/j.soard.2021.11.015

Cite this

@article{58da7f1a55af4256be4a6e4ba42061bc,

title = "ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis",

author = "Mazzini, \{Guilherme S.\} and Toms Augustin and Sabrena Noria and Carlos Romero-Marrero and Na Li and Bilal Hameed and Dan Eisenberg and Azagury, \{Dan E.\} and Sayeed Ikramuddin",

note = "Funding Information: B. Hameed reports grant support from Gilead, Intercept, Genfit, Pliant Therapeutics, Novo Nordisk, and Cyma Bay; serving on the advisory board for Mallinckrodt and Pleiogenix; serving as a consultant for Gilead and Pioneering Medicine VII, Inc; stock held by spouse from Intercept Pharmaceuticals; and stock held by self from Pleiogenix. D.E. Azagury reports being a consultant for and owning stock from Form Health and GI windows; stock and scientific advisory board membership for Endolumik; and being a consultant for Verily. S. Ikramuddin reports being on the advisory board for Novo Nordisk and receiving grant support from ReShape Life Sciences and NIH. All other authors have nothing to disclose. Funding Information: Sayeed Ikramuddin is funded by NIH grants 1R01DK12832501 and 5R21DK12283202.",

year = "2022",

month = mar,

doi = "10.1016/j.soard.2021.11.015",

language = "English",

volume = "18",

pages = "314--325",

journal = "Surgery for Obesity and Related Diseases",

issn = "1550-7289",

number = "3",

}

TY - JOUR

T1 - ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis

AU - Mazzini, Guilherme S.

AU - Augustin, Toms

AU - Noria, Sabrena

AU - Romero-Marrero, Carlos

AU - Li, Na

AU - Hameed, Bilal

AU - Eisenberg, Dan

AU - Azagury, Dan E.

AU - Ikramuddin, Sayeed

N1 - Funding Information: B. Hameed reports grant support from Gilead, Intercept, Genfit, Pliant Therapeutics, Novo Nordisk, and Cyma Bay; serving on the advisory board for Mallinckrodt and Pleiogenix; serving as a consultant for Gilead and Pioneering Medicine VII, Inc; stock held by spouse from Intercept Pharmaceuticals; and stock held by self from Pleiogenix. D.E. Azagury reports being a consultant for and owning stock from Form Health and GI windows; stock and scientific advisory board membership for Endolumik; and being a consultant for Verily. S. Ikramuddin reports being on the advisory board for Novo Nordisk and receiving grant support from ReShape Life Sciences and NIH. All other authors have nothing to disclose. Funding Information: Sayeed Ikramuddin is funded by NIH grants 1R01DK12832501 and 5R21DK12283202.

PY - 2022/3

Y1 - 2022/3

UR - https://www.scopus.com/pages/publications/85121720835

U2 - 10.1016/j.soard.2021.11.015

DO - 10.1016/j.soard.2021.11.015

M3 - Article

C2 - 34953742

AN - SCOPUS:85121720835

SN - 1550-7289

VL - 18

SP - 314

EP - 325

JO - Surgery for Obesity and Related Diseases

JF - Surgery for Obesity and Related Diseases

IS - 3

ER -

ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis

Access to Document

Other files and links

Cite this